The Drug That Just Doubled Pancreatic Cancer Survival

The fundamental problem is biological. About 90% of pancreatic cancers are driven by mutations in a protein called KRAS, which acts like a stuck "on" switch for cell growth. Scientists have known this for decades. The trouble is that KRAS was considered "undruggable" for most of that time; its smooth, featureless surface gave drug developers nothing to grab onto. It was like trying to pick up a greased bowling ball.

The first breakthrough came with drugs targeting one specific KRAS mutation called G12C (think Amgen's Lumakras and Mirati/BMS's Krazati). But those drugs only work on the inactive form of the protein, and G12C is relatively rare in pancreatic cancer. They changed the game in lung cancer but barely moved the dial for the organ that needed help most.

How Daraxonrasib Flipped the Script

Revolution Medicines took a fundamentally different approach. Instead of waiting for KRAS to switch off and then trapping it, daraxonrasib attacks the protein while it's on and actively signaling. The drug first latches onto a helper protein called cyclophilin A, and that complex then wraps around active KRAS like a molecular bear hug, blocking it from sending growth signals downstream.

This "RAS(ON)" strategy has two big advantages. First, it works across multiple KRAS mutation types (G12D, G12V, and others), not just G12C. Second, because it targets the active form, it hits the cancer where it actually lives. The trial enrolled patients regardless of which specific KRAS mutation they carried, and the drug worked across the board.

Phase 1/2 data in treatment-naïve patients (first-line setting) looked even more impressive: a 47% response rate as a single agent and a 92% disease control rate. When combined with standard frontline chemo, 90% of patients were alive at six months. Those numbers are almost unheard of in pancreatic cancer.

The FDA Said "Go" Before the Drug Is Even Approved

On April 30, 2026, the FDA issued a "safe to proceed" letter authorizing an expanded access program (EAP) for daraxonrasib. By late May, Revolution confirmed it was already shipping the drug to physicians and patients.

This kind of urgency is rare. Expanded access programs exist for situations where patients have a serious, life-threatening disease and have run out of options. To qualify, patients need metastatic pancreatic cancer that has progressed on prior treatment, no access to a relevant clinical trial, and a physician willing to submit the request on their behalf. The drug itself is provided at no cost.

Daraxonrasib also carries Breakthrough Therapy and Orphan Drug designations. Perhaps most notably, it received a Commissioner's National Priority Voucher (CNPV) in October 2025, which could compress the FDA review timeline to as little as one to two months once Revolution files for approval.

Wall Street Is Already Pricing in a Blockbuster

Revolution Medicines went public in 2020 at $17 per share. By the time of the ASCO presentation, the stock had climbed nearly ten-fold, giving the company a market cap comparable to established names like Biogen. Some analysts estimate the pancreatic cancer opportunity alone could exceed $10 billion in peak sales.

Truist has said it expects Revolution to "own the PDAC market for the foreseeable future," noting that any future competitor would need to run massive trials against daraxonrasib as the new standard of care; an expensive, ethically complicated bar to clear.

But the ambitions stretch well beyond pancreatic cancer. Revolution's pipeline includes zoldonrasib (targeting the G12D mutation specifically), elironrasib (targeting G12C with an early response rate of 56% in lung cancer), and a G12V-selective inhibitor. The company is building a full franchise around the idea that RAS(ON) is the better way to attack these cancers.

What Happens Next

The competitive landscape is heating up. Roche's divarasib, AstraZeneca, Verastem, and others are all chasing pieces of the RAS inhibitor market. But in pancreatic cancer specifically, Revolution has a commanding head start.

The more immediate question is how quickly daraxonrasib moves from early access to full approval, and whether the first-line combination data (already looking strong in early trials) can extend its reach even further. If the drug works as well up front as it does in the second line, the entire treatment paradigm for pancreatic cancer could shift within a couple of years.

For a disease that has resisted meaningful progress for decades, doubling survival isn't just a good result. It's the kind of moment that makes researchers, patients, and investors all stop and stare at the same data. That almost never happens in this field.

The Cancer That Had No Good Options Just Got One

Merck's antibody-drug conjugate sac-TMT just became the first ADC to beat chemotherapy on both overall survival and progression-free survival in advanced endometrial cancer. For patients who'd exhausted chemo and immunotherapy, this Phase 3 win could rewrite the treatment playbook.